New Antibody-drug Conjugate Shows Clinical Benefit for Advanced Platinum-resistant Ovarian Cancer Summary: Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial presented at the American Association for Cancer Research (AACR) […]